About Shize Bio
Shize Bio is a company based in Minhang (China) founded in 2021 by Michael Lee.. Shize Bio has raised $41.7 million across 4 funding rounds from investors including Qiming Venture Partners, Frees Fund and Lilly Asia Ventures. Shize Bio operates in a competitive market with competitors including Semma Therapeutics, UCB, Cellino, Aspen Neuroscience and Ocata Therapeutics, among others.
- Headquarter Minhang, China
- Founders Michael Lee
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$41.7 M (USD)
in 4 rounds
-
Latest Funding Round
$14.01 M (USD), Series B
Oct 23, 2024
-
Investors
Qiming Venture Partners
& 10 more
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Shize Bio
Shize Bio has successfully raised a total of $41.7M across 4 strategic funding rounds. The most recent funding activity was a Series B round of $14.01 million completed in October 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 4
- Last Round Series B — $14.0M
- First Round First Round
- Investors Count 11
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct, 2024 | Amount | Series B - Shize Bio | Valuation | Frees Fund , Qiming Venture Partners | |
| Apr, 2023 | Amount | Series A - Shize Bio | Valuation | Qiming Venture Partners |
|
| Nov, 2022 | Amount | Series A - Shize Bio | Valuation | Qiming Venture Partners , zxrc |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Shize Bio
Shize Bio has secured backing from 11 investors, including venture fund and institutional investors. Prominent investors backing the company include Qiming Venture Partners, Frees Fund and Lilly Asia Ventures. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Tech focused VC firm investing in early stage companies in the US & China
|
Founded Year | Domain | Location | |
|
Venture capital investments are directed toward multiple sectors.
|
Founded Year | Domain | Location | |
|
Investments in biomedical companies are directed by Lilly Asia Ventures.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Shize Bio
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Shize Bio
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Shize Bio Comparisons
Competitors of Shize Bio
Shize Bio operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Semma Therapeutics, UCB, Cellino, Aspen Neuroscience and Ocata Therapeutics, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Provider of bio-artificial pancreas for Type 1 Diabetes treatment
|
|
| domain | founded_year | HQ Location |
Therapies for immunological and neurological disorders are developed.
|
|
| domain | founded_year | HQ Location |
Developer of autologous cell therapies
|
|
| domain | founded_year | HQ Location |
Provider of genomic-based personalised pluripotent stem cell therapy
|
|
| domain | founded_year | HQ Location |
Stem cell therapies for macular degeneration disorders are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Shize Bio
Frequently Asked Questions about Shize Bio
When was Shize Bio founded?
Shize Bio was founded in 2021 and raised its 1st funding round 1 year after it was founded.
Where is Shize Bio located?
Shize Bio is headquartered in Minhang, China. It is registered at Minhang, Shanghai, China.
Who is the current CEO of Shize Bio?
Michael Lee is the current CEO of Shize Bio. They have also founded this company.
Is Shize Bio a funded company?
Shize Bio is a funded company, having raised a total of $41.7M across 4 funding rounds to date. The company's 1st funding round was a Series A of $27.68M, raised on Jan 10, 2022.
What does Shize Bio do?
Shize Bio was founded in 2021 and is based in Minhang, China. Operations focus on the biotechnology sector, where a pluripotent stem cell platform has been engineered through gene-editing technology. Therapeutics are developed to address degenerative diseases, including Parkinsons disease. The approach integrates stem-cell derivation with targeted genetic modifications for potential clinical applications in neurology.
Who are the top competitors of Shize Bio?
Shize Bio's top competitors include Semma Therapeutics, UCB and Cellino.
Who are Shize Bio's investors?
Shize Bio has 11 investors. Key investors include Qiming Venture Partners, Frees Fund, Lilly Asia Ventures, HSG, and Qicheng Capital.